Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 50 years old at the time of their first treatment
- People who have been diagnosed with classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL), or Primary mediastinal large B-cell lymphoma (PMBCL)
- People whose cancer went into complete remission (meaning no signs of cancer were found) after their first course of chemotherapy, using specific treatment regimens depending on their cancer type (confirm with trial site)
- People who have been in remission for at least 3 years but no more than 10 years since finishing treatment
- People who received a total dose of at least 200 mg/m² of the chemotherapy drug doxorubicin (also called adriamycin), which is equivalent to at least 4 cycles of chemotherapy
- People who have had a heart ultrasound (echocardiogram), including a specific type called a 2D speckle strain echocardiogram, performed within the three months before enrolling
- People who are willing to sign a consent form showing they understand the study and agree to take part voluntarily
Who may not be able to join:
- People who have been diagnosed with another cancer at the start of the study, except for certain minor skin cancers or a fully treated early-stage cervical condition
- People who have had a second round of chemotherapy or a stem cell transplant
- People who are unable to perform physical activity
- People with moderate to severe nerve damage (grade 3 or higher neuropathy)
- People with spinal fractures, narrowing of the spinal canal, or other bone fractures
- People with certain heart or blood pressure conditions of a moderate to severe level, including irregular heartbeat, high blood pressure, reduced heart pumping function, heart muscle inflammation, fluid around the heart, high blood pressure in the lungs, stiffening of the heart, significant heart valve problems, or reduced right-side heart function (confirm severity grading with trial site)
- People who have had a blood clot in a vein or artery in the past 6 months
- People who have had a moderate to severe bleeding episode in the past 6 months
- People with ongoing, long-term swelling in their arms or legs (chronic lymphedema)
- People being treated with systemic (whole-body) medication for a rheumatic disease or inflammatory bowel disease
- People with any fluid around their lungs (pleural effusion)
- People who are pregnant
- People who are unwilling to attend all required visits and follow all study procedures for the full duration of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carla Minoia, MD, Bari, IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia
Phone: 0599769918
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Global quality of life
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.